https://pharmatlas.org/ 2026-04-06T05:49:59+00:00 https://pharmatlas.org/ https://pharmatlas.org/lib/exe/fetch.php?media=logo.png text/html 2026-02-13T17:58:45+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:lipids:alirocumab&rev=1771005525&do=diff Alirocumab (Praluent®) Drug Overview Drug Class PCSK9 Inhibitors Mechanism PCSK9 Monoclonal Antibody Primary Uses ASCVD; Familial Hypercholesterolemia Route Subcutaneous Injection Dosing Interval Every 2–4 weeks LDL Reduction ~50–60% Metabolism Reticuloendothelial degradation Elimination text/html 2026-02-13T17:47:21+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:lipids:atorvastatin&rev=1771004841&do=diff Atorvastatin (Lipitor®) Drug Overview Drug Class Statins Mechanism HMG-CoA Reductase Inhibitor Primary Uses ASCVD Prevention; Hyperlipidemia Route Oral Dose Range 10–80 mg daily Intensity Moderate–High LDL Reduction 35–60% Metabolism CYP3A4 Half-life ~14 hours (active metabolites longer) text/html 2026-02-12T22:27:06+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:lipids:ezetimibe&rev=1770935226&do=diff Ezetimibe Ezetimibe is a cholesterol absorption inhibitor used to lower LDL cholesterol. It is most commonly used: • As add-on therapy to statins • In statin intolerance • When additional LDL reduction is required Ezetimibe is not first-line monotherapy for most patients. It is an adjunct drug. text/html 2026-02-13T17:53:10+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:lipids:pravastatin&rev=1771005190&do=diff Pravastatin (Pravachol®) Drug Overview Drug Class Statins Mechanism HMG-CoA Reductase Inhibitor Primary Uses Hyperlipidemia; ASCVD Prevention Route Oral Dose Range 10–80 mg daily Intensity Low–Moderate LDL Reduction 20–40% Metabolism Minimal CYP (non-CYP metabolism) text/html 2026-02-13T17:48:54+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:lipids:rosuvastatin&rev=1771004934&do=diff Rosuvastatin (Crestor®) Drug Overview Drug Class Statins Mechanism HMG-CoA Reductase Inhibitor Primary Uses ASCVD Prevention; Hyperlipidemia Route Oral Dose Range 5–40 mg daily Intensity Moderate–High LDL Reduction 45–63% Metabolism Minimal CYP2C9 Half-life ~19 hours text/html 2026-02-13T17:51:37+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:lipids:simvastatin&rev=1771005097&do=diff Simvastatin (Zocor®) Drug Overview Drug Class Statins Mechanism HMG-CoA Reductase Inhibitor Primary Uses Hyperlipidemia; ASCVD Prevention Route Oral Dose Range 10–40 mg daily Intensity Low–Moderate LDL Reduction 25–45% Metabolism CYP3A4 Half-life ~2–3 hours (active metabolites longer) text/html 2026-02-12T22:25:20+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:lipids:start&rev=1770935120&do=diff Antilipemics Antilipemics are drugs that reduce atherogenic lipoproteins — primarily LDL cholesterol — in order to reduce atherosclerotic cardiovascular disease (ASCVD). This module focuses on: • Drug mechanisms • LDL reduction potency • Outcome data • Adverse effects • Clinical selection strategies text/html 2026-02-13T17:45:49+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:lipids:statins&rev=1771004749&do=diff Statins Statins are HMG-CoA reductase inhibitors and are first-line therapy for LDL reduction and prevention of atherosclerotic cardiovascular disease (ASCVD). They are outcome-driven therapies. Primary Benefits: * ↓ Myocardial infarction * ↓ Ischemic stroke * ↓ Cardiovascular mortality